RxDoctor Payments Data

George Labrot, MD

Internal Medicine · Santa Monica, CANPI 1447295357

Payments from drug & device makers

$2,994in general payments, 2019–2025

Across 93 payments — averaging $32.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Harmony Biosciences LLC$828
  • Amgen$444
  • Regeneron Healthcare Solutions, Inc.$394
  • Lilly USA, LLC$203
  • Sanofi$191
  • Boehringer Ingelheim$185
  • plus $748 from 12 others

What the payments were for

  • Food & beverage$2,53885%
  • Education$45515%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,994 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$85,090
Medicare patients
227
Services billed
3,712

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban40$39,728
OzempicSemaglutide20$31,176
Breo ElliptaFluticasone/Vilanterol28$20,271
Spiriva HandihalerTiotropium Bromide12$12,385
Arnuity ElliptaFluticasone Furoate12$5,745
BrilintaTicagrelor13$5,330
Albuterol Sulfate HfaAlbuterol Sulfate53$2,503
Levothyroxine Sodium117$1,578
Atorvastatin Calcium125$1,525
Rosuvastatin Calcium62$1,437
Gabapentin51$924
Tamsulosin Hcl43$909
Allopurinol41$740
Azelastine Hcl32$676
Famotidine27$587

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$51$39,72840 claims
Novo NordiskOzempic$106$31,17620 claims
GSKBreo Ellipta, Arnuity Ellipta$58$26,01640 claims
AstraZenecaBrilinta$134$5,33013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Santa Monica

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →